Journal of
eISSN: 2373-633X
Submit manuscript...
Editorial Volume 7 Issue 5
Tamoxifen, chemotherapy or both treatments inhibits the serum concentration of inhibin b and antimullerian hormone in premenopausal patients
Lüthy Isabel,1 Pérez Piñero Cecilia,1 Gass Hugo,2 Woscoboinik De Levin Rosa,2 Aiello Gustavo J2
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
1Institute of Biology and Experimental Medicine, Argentina
2Oncologic Foundation, Argentina
Correspondence: Gustavo Jose Aiello, Oncologic Foundation Encuentro, Viamonte 2565 4to B, Buenos Aires, Argentina, Tel 4962-5108
Received: March 10, 2017 | Published: March 17, 2017
Citation: Isabel L, Cecilia PP, Hugo G, et al. Tamoxifen, chemotherapy or both treatments inhibits the serum concentration of inhibin b and antimullerian hormone in premenopausal patients. J Cancer Prev Curr Res. 2017;7(5):158-159. DOI: 10.15406/jcpcr.2017.07.00252
Introduction
Breast cancer is the leading cause of cancer death in women in our country, with about 5400 deaths and 19,000 new diagnoses by year. Luminal tumors, which express estrogen receptors, are treated with tamoxifen (TAM). If tumors are spread, chemotherapy is added, and negative triple tumors, because of lack of specific therapy, are treated with chemotherapy.1
The antimullerian hormone (AMH) and Inhibin-B have been suggested as markers for evaluating ovarian reserve in breast cancer patients treated with chemotherapy.2
Objective
Establish which patients have ovarian reserve and therefore should avoid pregnancy during therapy.
Methods
Serum concentrations of AMH and Inhibin-B were measured by commercially available ELISA Gen II kits from Beckman Coulter. Serum samples from 19 premenopausal patients (7 treated with TAM, 4 with chemotherapy and 8 with TAM + chemotherapy) and 7 controls were analyzed. Of the patients, 2/3 were in amenorrhea after treatment
Results
- Both Inhbin-B and AMH had undetectable levels in the 7 patients treated with tamoxifen and in 7/8 patients treated with tamoxifen + chemotherapy. In the latter case one of the patients presented high levels of both.
- In the case of treatment with chemotherapy, three of the patients had very low levels of Inhibin-B and undetectable AMH whereas one of them presented a high level of Inhibin-B and AMH intermediate.
Conclusion
Both determinations were equivalent to determine the ovarian reserve of the patients.
- Treatment with tamoxifen inhibited reproductive capacity and overall treatment with chemotherapy as well.
- However in a few patients the ovarian reserve is still elevated despite treatment and pregnancy should be avoided (Figure 1).
Figure 1
Funding
None.
Acknowledgements
None.
Conflicts of interest
The authors declare that there is no conflict of interest.
References
- A Goldhrisch, EP Winer, AS Coates, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology. 2013;24()9: 2206–2223.
- HI Su, MD Sammel, J Green, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010;116(3):592–599.
©2017 Isabel, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.